Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

A 2-STAGE, PHASE 2, DOUBLE-MASKED, RANDOMIZED, VEHICLE CONTROLLED, DOSE RESPONSE TRIAL OF PF-04217329 AND THE MARKETED FORMULATION OF LATANOPROST IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00572455

Enrollment

318

Registered

2007-12-13

Start date

2007-12-11

Completion date

2009-06-26

Last updated

2021-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Open-Angle Glaucoma, Ocular Hypertension

Keywords

Open-Angle Glaucoma, Ocular Hypertension

Brief summary

To evaluate the safety and efficacy of PF-04217329.

Interventions

DRUGPF-04217329 - Lowest Dose

1 drop of lowest dose PF-04217329, once a day, per dosed eye for duration of study.

DRUGPF-04217329 - Low Dose

1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.

DRUGPF-04217329 - Middle Dose

1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.

DRUGPF-04217329 - High Middle Dose

1 drop of high middle dose PF-04217329, once a day, per dosed eye for duration of study.

DRUGPF-04217329 - High Dose

1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.

DRUGPF-4217329 - Highest Dose

1 drop of highest dose PF-04217329, once a day, per dosed eye for duration of study.

DRUGPF-04217329 - Vehicle

1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.

DRUGLatanoprost Vehicle

1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.

DRUGLatanoprost 0.005%

1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of primary open-angle glaucoma (including pigmentary or pseudoexfoliative) or ocular hypertension in 1 or both eyes. * Qualifying intraocular pressure (IOP) in the same eye at the Eligibility 1 and 2 measurements.

Exclusion criteria

* Closed/barely open anterior chamber angle or a history of acute angle closure in either eye. * Anticipate the need to initiate or modify medication (systemic or topical) that is known to affect intraocular pressure (IOP) during the study period.

Design outcomes

Primary

Measure	Time frame	Description
Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Stage I: Baseline, Day 14	Diurnal IOP was defined as the mean IOP over 24 hours. IOP was measured using Goldmann applanation tonometer. IOP was measured in both the eyes, and the eye with higher IOP reading at the 2 eligibility visits was referred as 'study eye' for efficacy assessment. If both the measurements were equal, right eye was selected as the study eye. IOP was measured twice in the same eye, and if the difference between 2 measurements was less than or equal to 2 millimeter of mercury (mmHg), the mean of the 2 readings was recorded as the IOP at that time point. If the difference between 2 readings was greater than 2 mmHg, a third consecutive reading was taken and the median IOP was recorded as the IOP at that time point. Mean IOP was reported as the average of individual participants' mean or median IOP values. Change from baseline = diurnal IOP at baseline - diurnal IOP at Day 14.
Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Stage II: Baseline, Day 28	Diurnal IOP was defined as the mean IOP over 24 hours. IOP was measured using Goldmann applanation tonometer. IOP was measured in both the eyes, and the eye with higher IOP reading at the 2 eligibility visits was referred as 'study eye' for efficacy assessment. If both the measurements were equal, right eye was selected as the study eye. IOP was measured twice in the same eye, and if the difference between 2 measurements was less than or equal to 2 mmHg, the mean of the 2 readings was recorded as the IOP at that time point. If the difference between 2 readings was greater than 2 mmHg, a third consecutive reading was taken and the median IOP was recorded as the IOP at that time point. Mean IOP was reported as the average of individual participants' mean or median IOP values. Change from baseline = diurnal IOP at baseline - diurnal IOP at Day 28.
Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage I	Stage I: Day 1 up to 28 days after last dose of study medication (up to 44 days)	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study medication and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Ocular AEs were the events which were localized in the ocular region.
Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage II	Stage II: Day 1 up to 28 days after last dose of study medication (up to 59 days)	An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study medication and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Ocular AEs were the events which were localized in the ocular region.

Secondary

Measure	Time frame	Description
Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Stage I: 8 ante meridiem (AM) on Day 1, 8 AM, 10 AM, 1 post meridiem (PM), 4 PM on Day 7, and 14	IOP was measured using Goldmann applanation tonometer. IOP was measured in both the eyes, and the eye with higher IOP reading at the 2 eligibility visits was referred as 'study eye' for efficacy assessment. If both the measurements were equal, right eye was selected as the study eye. IOP was measured twice in the same eye, and if the difference between 2 measurements was less than or equal to 2 mmHg, the mean of the 2 readings was recorded as the IOP at that time point. If the difference between 2 readings was greater than 2 mmHg, a third consecutive reading was taken and the median IOP was recorded as the IOP at that time point. Mean IOP was reported as the average of individual participants' mean or median IOP values.
Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Stage I: 8 AM, 10 AM, 1 PM, 4 PM on Day 0 (Baseline), 8 AM on Day 1, 8 AM, 10 AM, 1 PM, 4 PM on Day 7, and 14	IOP was measured using Goldmann applanation tonometer. IOP was measured in both eyes, and the eye with higher IOP reading at 2 eligibility visits was referred as 'study eye' for efficacy assessment. If both measurements were equal, right eye was selected as the study eye. IOP was measured twice in the same eye, and if the difference between 2 measurements was less than or equal to 2 mmHg, the mean of the 2 readings was recorded as the IOP at that time point. If the difference between 2 readings was greater than 2 mmHg, a third consecutive reading was taken and the median IOP was recorded as the IOP at that time point. Mean IOP was reported as the average of individual participants' mean or median IOP values. Change from baseline = baseline IOP - post-baseline IOP. Change at various post-dose time points was calculated from the baseline values at same time points on Day 0 (for example, value at 8 AM on Day 0 was used as baseline value for 8 AM value on Day 1, 7 and 14).
Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Stage II: 8 AM on Day 1; 8 AM, 10 AM, 1 PM, 4 PM on Days 7, 14, and 28	IOP was measured using Goldmann applanation tonometer. IOP was measured in both the eyes, and the eye with higher IOP reading at the 2 eligibility visits was referred as 'study eye' for efficacy assessment. If both the measurements were equal, right eye was selected as the study eye. IOP was measured twice in the same eye, and if the difference between 2 measurements was less than or equal to 2 mmHg, the mean of the 2 readings was recorded as the IOP at that time point. If the difference between 2 readings was greater than 2 mmHg, a third consecutive reading was taken and the median IOP was recorded as the IOP at that time point. Mean IOP was reported as the average of individual participants' mean or median IOP values.
Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Stage II: 8 AM, 10 AM, 1 PM, and 4 PM on Day 0 (Baseline), 8 AM on Day 1; 8 AM, 10 AM, 1 PM, 4 PM on Days 7, 14, and 28	IOP was measured using Goldmann applanation tonometer. IOP was measured in both eyes, and the eye with higher IOP reading at 2 eligibility visits was referred as 'study eye' for efficacy assessment. If both measurements were equal, right eye was selected as the study eye. IOP was measured twice in the same eye, and if the difference between 2 measurements was less than or equal to 2 mmHg, the mean of the 2 readings was recorded as the IOP at that time point. If the difference between 2 readings was greater than 2 mmHg, a third consecutive reading was taken and the median IOP was recorded as the IOP at that time point. Mean IOP was reported as the average of individual participants' mean or median IOP values. Change from baseline = baseline IOP - post-baseline IOP. Change at various post-dose time points was calculated from the baseline values at same time points on Day 0 (for example, value at 8 AM on Day 0 was used as baseline value for 8 AM value on Day 1, 7, 14 and 28).
Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage I	Stage I: Day 1 up to Day 14	Percentage of participants who reached an IOP of less than or equal to (\<=) 18 mmHg by post-eligibility visit (Day 1) and maintained an IOP \<= 18 mm Hg across all post-eligibility visits in Stage I were reported. IOP was measured using Goldmann applanation tonometer.
Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage II	Stage II: Day 1 up to Day 28	Percentage of participants who reached an IOP \<= 18 mmHg by post-eligibility visit (Day 1) and maintained an IOP \<= 18 mm Hg across all post-eligibility visits in Stage II were reported. IOP was measured using Goldmann applanation tonometer.

Countries

United States

Participant flow

Participants by arm

Arm	Count
Taprenepag 0.0025% (Stage I) Participants self-administered 1 drop (27 microliter \[mcL\]) of taprenepag (taprenepag isopropyl, PF-04217329) 0.0025 percent (%) ophthalmic solution into each eye once daily for 14 days in Stage I.	9
Taprenepag 0.005% (Stage I) Participants self-administered 1 drop (27 mcL) of taprenepag (taprenepag isopropyl, PF-04217329) 0.005% ophthalmic solution into each eye once daily for 14 days in Stage I.	9
Taprenepag 0.01% (Stage I) Participants self-administered 1 drop (27 mcL) of taprenepag (taprenepag isopropyl, PF-04217329) 0.01% ophthalmic solution into each eye once daily for 14 days in Stage I.	9
Taprenepag 0.015% (Stage I) Participants self-administered 1 drop (27 mcL) of taprenepag (taprenepag isopropyl, PF-04217329) 0.015% ophthalmic solution into each eye once daily for 14 days in Stage I.	10
Taprenepag 0.02% (Stage I) Participants self-administered 1 drop (27 mcL) of taprenepag (taprenepag isopropyl, PF-04217329) 0.02% ophthalmic solution into each eye once daily for 14 days in Stage I.	9
Taprenepag 0.03% (Stage I) Participants self-administered 1 drop (27 mcL) of taprenepag (taprenepag isopropyl, PF-04217329) 0.03% ophthalmic solution into each eye once daily for 14 days in Stage I.	9
Taprenepag Vehicle (Stage I) Participants self-administered 1 drop (27 mcL) of vehicle matched to taprenepag (taprenepag isopropyl, PF-04217329) ophthalmic solution into each eye once daily for 14 days in Stage I.	12
Latanoprost Vehicle and Taprenepag 0.005% (Stage II) Participants self-administered 1 drop (27 mcL) of vehicle matched to latanoprost ophthalmic solution followed by 1 drop (27 mcL) of taprenepag (taprenepag isopropyl, PF-04217329) 0.005% ophthalmic solution after 5 minutes, into each eye once daily for 28 days in Stage II.	35
Latanoprost Vehicle and Taprenepag 0.01% (Stage II) Participants self-administered 1 drop (27 mcL) of vehicle matched to latanoprost ophthalmic solution followed by 1 drop (27 mcL) of taprenepag (taprenepag isopropyl, PF-04217329) 0.01% ophthalmic solution after 5 minutes, into each eye once daily for 28 days in Stage II.	36
Latanoprost Vehicle and Taprenepag 0.015% (Stage II) Participants self-administered 1 drop (27 mcL) of vehicle matched to latanoprost ophthalmic solution followed by 1 drop (27 mcL) of taprenepag (taprenepag isopropyl, PF-04217329) 0.015% ophthalmic solution after 5 minutes, into each eye once daily for 28 days in Stage II.	36
Latanoprost 0.005% and Taprenepag 0.005% (Stage II) Participants self-administered 1 drop (27 mcL) of latanoprost 0.005% ophthalmic solution followed by 1 drop (27 mcL) of taprenepag (taprenepag isopropyl, PF-04217329) 0.005% ophthalmic solution after 5 minutes, into each eye once daily for 28 days in Stage II.	36
Latanoprost 0.005% and Taprenepag 0.01% (Stage II) Participants self-administered 1 drop (27 mcL) of latanoprost 0.005% ophthalmic solution followed by 1 drop (27 mcL) of taprenepag (taprenepag isopropyl, PF-04217329) 0.01% ophthalmic solution after 5 minutes, into each eye once daily for 28 days in Stage II.	36
Latanoprost 0.005% and Taprenepag 0.015% (Stage II) Participants self-administered 1 drop (27 mcL) of latanoprost 0.005% ophthalmic solution followed by 1 drop (27 mcL) of taprenepag (taprenepag isopropyl, PF-04217329) 0.015% ophthalmic solution after 5 minutes, into each eye once daily for 28 days in Stage II.	36
Latanoprost 0.005% and Taprenepag Vehicle (Stage II) Participants self-administered 1 drop (27 mcL) of latanoprost 0.005% ophthalmic solution followed by 1 drop (27 mcL) of vehicle matched to taprenepag (taprenepag isopropyl, PF-04217329) ophthalmic solution after 5 minutes, into each eye once daily for 28 days in Stage II.	35
Total	317

Withdrawals & dropouts

Period	Reason	FG004	FG005	FG007	FG008	FG009	FG010	FG011	FG012	FG013
Stage I (14 Days)	Adverse Event	0	3	0	0	0	0	0	0	0
Stage I (14 Days)	Other	1	0	0	0	0	0	0	0	0
Stage II (28 Days)	Adverse Event	0	0	0	1	3	3	4	5	1
Stage II (28 Days)	Death	0	0	0	1	0	0	0	0	0
Stage II (28 Days)	Other	0	0	0	1	0	0	0	0	0
Stage II (28 Days)	Randomized, but not treated	0	0	0	0	0	0	0	0	1
Stage II (28 Days)	Withdrawal by Subject	0	0	1	0	0	2	0	0	0

Baseline characteristics

Characteristic	Taprenepag 0.0025% (Stage I)	Taprenepag 0.005% (Stage I)	Taprenepag 0.01% (Stage I)	Taprenepag 0.015% (Stage I)	Taprenepag 0.02% (Stage I)	Taprenepag 0.03% (Stage I)	Taprenepag Vehicle (Stage I)	Latanoprost Vehicle and Taprenepag 0.005% (Stage II)	Latanoprost Vehicle and Taprenepag 0.01% (Stage II)	Latanoprost Vehicle and Taprenepag 0.015% (Stage II)	Latanoprost 0.005% and Taprenepag 0.005% (Stage II)	Latanoprost 0.005% and Taprenepag 0.01% (Stage II)	Latanoprost 0.005% and Taprenepag 0.015% (Stage II)	Latanoprost 0.005% and Taprenepag Vehicle (Stage II)	Total
Age, Continuous	59.1 years STANDARD_DEVIATION 13	59.1 years STANDARD_DEVIATION 8.1	64.1 years STANDARD_DEVIATION 6.8	51.8 years STANDARD_DEVIATION 10.4	64.6 years STANDARD_DEVIATION 9.6	60.3 years STANDARD_DEVIATION 8.5	62.1 years STANDARD_DEVIATION 6.5	62.5 years STANDARD_DEVIATION 10.7	63.8 years STANDARD_DEVIATION 11.4	66.6 years STANDARD_DEVIATION 10.1	66.7 years STANDARD_DEVIATION 11.4	64.1 years STANDARD_DEVIATION 9.1	63.7 years STANDARD_DEVIATION 9.4	68.9 years STANDARD_DEVIATION 10.2	64.1 years STANDARD_DEVIATION 10.5
Sex: Female, Male Female	4 Participants	7 Participants	6 Participants	10 Participants	3 Participants	6 Participants	8 Participants	25 Participants	22 Participants	21 Participants	24 Participants	25 Participants	21 Participants	22 Participants	204 Participants
Sex: Female, Male Male	5 Participants	2 Participants	3 Participants	0 Participants	6 Participants	3 Participants	4 Participants	10 Participants	14 Participants	15 Participants	12 Participants	11 Participants	15 Participants	13 Participants	113 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk	EG009 affected / at risk	EG010 affected / at risk	EG011 affected / at risk	EG012 affected / at risk	EG013 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	3 / 9	3 / 9	0 / 9	5 / 10	5 / 9	9 / 9	4 / 12	18 / 35	20 / 36	27 / 36	24 / 36	27 / 36	26 / 36	15 / 35
serious Total, serious adverse events	0 / 9	0 / 9	0 / 9	0 / 10	0 / 9	0 / 9	0 / 12	0 / 35	1 / 36	2 / 36	0 / 36	0 / 36	0 / 36	0 / 35

Outcome results

Primary

Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I

Diurnal IOP was defined as the mean IOP over 24 hours. IOP was measured using Goldmann applanation tonometer. IOP was measured in both the eyes, and the eye with higher IOP reading at the 2 eligibility visits was referred as 'study eye' for efficacy assessment. If both the measurements were equal, right eye was selected as the study eye. IOP was measured twice in the same eye, and if the difference between 2 measurements was less than or equal to 2 millimeter of mercury (mmHg), the mean of the 2 readings was recorded as the IOP at that time point. If the difference between 2 readings was greater than 2 mmHg, a third consecutive reading was taken and the median IOP was recorded as the IOP at that time point. Mean IOP was reported as the average of individual participants' mean or median IOP values. Change from baseline = diurnal IOP at baseline - diurnal IOP at Day 14.

Time frame: Stage I: Baseline, Day 14

Population: ITT population included all randomized participants who received at least 1 dose of study medication. Last observation carried forward (LOCF) method was used to impute missing values.

Arm	Measure	Group	Value (MEAN)	Dispersion
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Baseline	25.97 mmHg	Standard Deviation 2.42
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Change at Day 14	3.65 mmHg	Standard Deviation 1.749
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Change at Day 14	5.40 mmHg	Standard Deviation 2.508
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Baseline	26.25 mmHg	Standard Deviation 2.4
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Baseline	25.90 mmHg	Standard Deviation 2.094
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Change at Day 14	7.18 mmHg	Standard Deviation 2.749
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Change at Day 14	6.48 mmHg	Standard Deviation 4.278
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Baseline	26.44 mmHg	Standard Deviation 1.56
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Baseline	28.10 mmHg	Standard Deviation 3.102
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Change at Day 14	6.00 mmHg	Standard Deviation 2.748
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Baseline	26.26 mmHg	Standard Deviation 1.831
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Change at Day 14	6.69 mmHg	Standard Deviation 4.563
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Baseline	26.04 mmHg	Standard Deviation 2.182
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I	Change at Day 14	0.64 mmHg	Standard Deviation 1.382

Comparison: Analysis was based on analysis of covariance (ANCOVA) model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.02890% CI: [0.78, 5.25]ANCOVA

Comparison: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [2.5, 6.96]ANCOVA

Comparison: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [4.33, 8.79]ANCOVA

Comparison: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [3.6, 7.95]ANCOVA

Comparison: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [2.74, 7.37]ANCOVA

Comparison: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [3.79, 8.25]ANCOVA

Primary

Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II

Diurnal IOP was defined as the mean IOP over 24 hours. IOP was measured using Goldmann applanation tonometer. IOP was measured in both the eyes, and the eye with higher IOP reading at the 2 eligibility visits was referred as 'study eye' for efficacy assessment. If both the measurements were equal, right eye was selected as the study eye. IOP was measured twice in the same eye, and if the difference between 2 measurements was less than or equal to 2 mmHg, the mean of the 2 readings was recorded as the IOP at that time point. If the difference between 2 readings was greater than 2 mmHg, a third consecutive reading was taken and the median IOP was recorded as the IOP at that time point. Mean IOP was reported as the average of individual participants' mean or median IOP values. Change from baseline = diurnal IOP at baseline - diurnal IOP at Day 28.

Time frame: Stage II: Baseline, Day 28

Population: ITT population included all randomized participants who received at least 1 dose of study medication. LOCF method was used to impute missing values.

Arm	Measure	Group	Value (MEAN)	Dispersion
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Baseline	25.75 mmHg	Standard Deviation 2.266
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Change at Day 28	7.35 mmHg	Standard Deviation 3.559
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Baseline	26.47 mmHg	Standard Deviation 2.563
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Change at Day 28	7.05 mmHg	Standard Deviation 2.875
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Baseline	26.69 mmHg	Standard Deviation 2.509
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Change at Day 28	7.14 mmHg	Standard Deviation 3.462
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Baseline	26.98 mmHg	Standard Deviation 2.813
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Change at Day 28	8.29 mmHg	Standard Deviation 3.817
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Baseline	26.36 mmHg	Standard Deviation 2.524
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Change at Day 28	9.10 mmHg	Standard Deviation 3.292
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Baseline	27.34 mmHg	Standard Deviation 2.876
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Change at Day 28	8.78 mmHg	Standard Deviation 3.592
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Baseline	26.81 mmHg	Standard Deviation 2.783
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II	Change at Day 28	6.74 mmHg	Standard Deviation 2.927

Comparison: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.17190% CI: [-0.21, 2.32]ANCOVA

Comparison: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.05390% CI: [0.22, 2.73]ANCOVA

Comparison: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to Latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.01890% CI: [0.56, 3.07]ANCOVA

Primary

Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage I

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study medication and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Ocular AEs were the events which were localized in the ocular region.

Time frame: Stage I: Day 1 up to 28 days after last dose of study medication (up to 44 days)

Population: ITT population included all randomized participants who received at least 1 dose of study medication.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Taprenepag 0.0025% (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage I	1 Participants
Taprenepag 0.005% (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage I	2 Participants
Taprenepag 0.01% (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage I	0 Participants
Taprenepag 0.015% (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage I	5 Participants
Taprenepag 0.02% (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage I	4 Participants
Taprenepag 0.03% (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage I	9 Participants
Taprenepag Vehicle (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage I	3 Participants

Primary

Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage II

An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study medication and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Ocular AEs were the events which were localized in the ocular region.

Time frame: Stage II: Day 1 up to 28 days after last dose of study medication (up to 59 days)

Population: ITT population included all randomized participants who received at least 1 dose of study medication.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Taprenepag 0.0025% (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage II	17 Participants
Taprenepag 0.005% (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage II	20 Participants
Taprenepag 0.01% (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage II	27 Participants
Taprenepag 0.015% (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage II	24 Participants
Taprenepag 0.02% (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage II	26 Participants
Taprenepag 0.03% (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage II	26 Participants
Taprenepag Vehicle (Stage I)	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage II	14 Participants

Secondary

Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II

IOP was measured using Goldmann applanation tonometer. IOP was measured in both eyes, and the eye with higher IOP reading at 2 eligibility visits was referred as 'study eye' for efficacy assessment. If both measurements were equal, right eye was selected as the study eye. IOP was measured twice in the same eye, and if the difference between 2 measurements was less than or equal to 2 mmHg, the mean of the 2 readings was recorded as the IOP at that time point. If the difference between 2 readings was greater than 2 mmHg, a third consecutive reading was taken and the median IOP was recorded as the IOP at that time point. Mean IOP was reported as the average of individual participants' mean or median IOP values. Change from baseline = baseline IOP - post-baseline IOP. Change at various post-dose time points was calculated from the baseline values at same time points on Day 0 (for example, value at 8 AM on Day 0 was used as baseline value for 8 AM value on Day 1, 7, 14 and 28).

Time frame: Stage II: 8 AM, 10 AM, 1 PM, and 4 PM on Day 0 (Baseline), 8 AM on Day 1; 8 AM, 10 AM, 1 PM, 4 PM on Days 7, 14, and 28

Population: ITT population included all randomized participants who received at least 1 dose of study medication. LOCF method was used to impute missing values. Here 'number analyzed' signifies participants evaluable each specified time points for each group, respectively.

Arm	Measure	Group	Value (MEAN)	Dispersion
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 1PM	24.84 mmHg	Standard Deviation 2.466
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7,14,28: 8AM	27.59 mmHg	Standard Deviation 2.098
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 10AM	25.74 mmHg	Standard Deviation 3.129
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 1PM	24.85 mmHg	Standard Deviation 2.501
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 4PM	24.83 mmHg	Standard Deviation 2.901
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 10AM	25.70 mmHg	Standard Deviation 3.089
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 1: 8AM	27.34 mmHg	Standard Deviation 1.525
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 4PM	24.87 mmHg	Standard Deviation 2.868
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 10AM	25.70 mmHg	Standard Deviation 3.089
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 1PM	24.84 mmHg	Standard Deviation 2.466
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 4PM	24.87 mmHg	Standard Deviation 2.868
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 1: 8AM	8.22 mmHg	Standard Deviation 4.071
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 8AM	9.24 mmHg	Standard Deviation 3.987
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 10AM	8.47 mmHg	Standard Deviation 3.754
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 1PM	7.60 mmHg	Standard Deviation 3.499
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 4PM	7.57 mmHg	Standard Deviation 3.525
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 8AM	8.74 mmHg	Standard Deviation 3.829
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 10AM	7.89 mmHg	Standard Deviation 4.568
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 1PM	6.89 mmHg	Standard Deviation 4.225
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 4PM	7.46 mmHg	Standard Deviation 3.725
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 8AM	7.99 mmHg	Standard Deviation 4.108
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 10AM	7.78 mmHg	Standard Deviation 3.987
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 1PM	6.54 mmHg	Standard Deviation 3.965
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 4PM	7.09 mmHg	Standard Deviation 3.938
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 10AM	26.44 mmHg	Standard Deviation 3.005
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 10AM	26.44 mmHg	Standard Deviation 3.005
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 10AM	7.49 mmHg	Standard Deviation 3.057
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 8AM	8.76 mmHg	Standard Deviation 3.459
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 1PM	6.47 mmHg	Standard Deviation 2.645
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 1: 8AM	6.29 mmHg	Standard Deviation 3.117
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7,14,28: 8AM	28.16 mmHg	Standard Deviation 2.333
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 1PM	25.67 mmHg	Standard Deviation 2.754
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 1: 8AM	28.21 mmHg	Standard Deviation 2.349
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 1PM	25.67 mmHg	Standard Deviation 2.754
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 10AM	7.00 mmHg	Standard Deviation 3.383
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 8AM	8.40 mmHg	Standard Deviation 3.501
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 4PM	6.24 mmHg	Standard Deviation 3.51
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 4PM	25.59 mmHg	Standard Deviation 3.04
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 4PM	25.59 mmHg	Standard Deviation 3.04
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 1PM	6.33 mmHg	Standard Deviation 2.837
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 4PM	6.51 mmHg	Standard Deviation 3.302
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 10AM	26.44 mmHg	Standard Deviation 3.005
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 10AM	6.83 mmHg	Standard Deviation 3.151
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 8AM	8.60 mmHg	Standard Deviation 3.254
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 1PM	25.67 mmHg	Standard Deviation 2.754
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 4PM	6.92 mmHg	Standard Deviation 3.552
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 1PM	6.99 mmHg	Standard Deviation 2.943
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 4PM	25.59 mmHg	Standard Deviation 3.04
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 1PM	26.19 mmHg	Standard Deviation 2.992
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 4PM	6.74 mmHg	Standard Deviation 4.48
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 8AM	8.55 mmHg	Standard Deviation 3.473
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 8AM	8.59 mmHg	Standard Deviation 3.317
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 4PM	25.86 mmHg	Standard Deviation 3.013
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 10AM	8.10 mmHg	Standard Deviation 3.328
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 1PM	7.17 mmHg	Standard Deviation 3.502
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 1: 8AM	7.66 mmHg	Standard Deviation 3.11
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7,14,28: 8AM	28.27 mmHg	Standard Deviation 2.155
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 1PM	7.07 mmHg	Standard Deviation 3.472
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 4PM	7.60 mmHg	Standard Deviation 3.388
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 10AM	6.92 mmHg	Standard Deviation 3.706
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 4PM	25.86 mmHg	Standard Deviation 3.013
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 10AM	26.66 mmHg	Standard Deviation 2.854
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 1PM	7.46 mmHg	Standard Deviation 3.576
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 1: 8AM	28.27 mmHg	Standard Deviation 2.155
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 10AM	7.22 mmHg	Standard Deviation 3.292
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 8AM	8.00 mmHg	Standard Deviation 3.851
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 10AM	26.70 mmHg	Standard Deviation 2.937
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 1PM	26.13 mmHg	Standard Deviation 2.949
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 1PM	26.13 mmHg	Standard Deviation 2.949
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 10AM	26.66 mmHg	Standard Deviation 2.854
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 4PM	25.87 mmHg	Standard Deviation 3.054
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 4PM	7.55 mmHg	Standard Deviation 3.392
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 1PM	26.04 mmHg	Standard Deviation 3.179
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 4PM	25.92 mmHg	Standard Deviation 3.293
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 10AM	26.94 mmHg	Standard Deviation 3.449
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 10AM	8.68 mmHg	Standard Deviation 4.674
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 1PM	25.92 mmHg	Standard Deviation 3.068
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 4PM	25.99 mmHg	Standard Deviation 3.206
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 10AM	27.06 mmHg	Standard Deviation 3.467
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 1PM	25.98 mmHg	Standard Deviation 3.042
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 4PM	26.00 mmHg	Standard Deviation 3.156
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 1: 8AM	9.72 mmHg	Standard Deviation 3.484
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 8AM	10.20 mmHg	Standard Deviation 3.497
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 1PM	7.51 mmHg	Standard Deviation 3.915
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 10AM	9.19 mmHg	Standard Deviation 3.646
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 1PM	8.02 mmHg	Standard Deviation 4.046
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 4PM	8.27 mmHg	Standard Deviation 3.161
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 8AM	9.50 mmHg	Standard Deviation 3.915
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 10AM	7.95 mmHg	Standard Deviation 3.9
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 1PM	7.03 mmHg	Standard Deviation 3.71
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 4PM	7.33 mmHg	Standard Deviation 3.649
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 4PM	6.94 mmHg	Standard Deviation 3.962
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 8AM	9.92 mmHg	Standard Deviation 3.845
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 1: 8AM	29.10 mmHg	Standard Deviation 2.714
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7,14,28: 8AM	29.03 mmHg	Standard Deviation 2.71
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 10AM	27.13 mmHg	Standard Deviation 3.453
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 10AM	26.42 mmHg	Standard Deviation 2.779
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 1PM	8.66 mmHg	Standard Deviation 4.073
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 10AM	26.42 mmHg	Standard Deviation 2.779
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 10AM	9.76 mmHg	Standard Deviation 3.467
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 8AM	11.22 mmHg	Standard Deviation 3.393
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 10AM	9.55 mmHg	Standard Deviation 3.561
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 1PM	8.83 mmHg	Standard Deviation 3.364
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 4PM	25.35 mmHg	Standard Deviation 3.117
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 4PM	25.35 mmHg	Standard Deviation 3.117
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 1PM	25.34 mmHg	Standard Deviation 2.707
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 1PM	25.34 mmHg	Standard Deviation 2.707
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 1: 8AM	9.87 mmHg	Standard Deviation 2.786
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 1: 8AM	28.63 mmHg	Standard Deviation 2.648
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 4PM	8.44 mmHg	Standard Deviation 2.888
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 10AM	9.61 mmHg	Standard Deviation 3.448
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 4PM	8.23 mmHg	Standard Deviation 3.42
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 10AM	26.42 mmHg	Standard Deviation 2.779
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 8AM	10.66 mmHg	Standard Deviation 3.741
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7,14,28: 8AM	28.63 mmHg	Standard Deviation 2.648
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 4PM	25.35 mmHg	Standard Deviation 3.117
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 8AM	10.94 mmHg	Standard Deviation 3.793
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 1PM	8.54 mmHg	Standard Deviation 3.043
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 1PM	25.34 mmHg	Standard Deviation 2.707
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 4PM	8.36 mmHg	Standard Deviation 3.721
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 4PM	26.20 mmHg	Standard Deviation 3.145
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 1PM	26.21 mmHg	Standard Deviation 3.297
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 1PM	9.17 mmHg	Standard Deviation 4.022
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 1PM	8.82 mmHg	Standard Deviation 4.037
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 4PM	8.55 mmHg	Standard Deviation 3.081
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 10AM	27.41 mmHg	Standard Deviation 3.423
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 8AM	10.52 mmHg	Standard Deviation 4.446
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 10AM	9.74 mmHg	Standard Deviation 3.743
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 10AM	9.56 mmHg	Standard Deviation 3.121
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 4PM	26.20 mmHg	Standard Deviation 3.145
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 1PM	8.86 mmHg	Standard Deviation 3.71
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 1PM	26.21 mmHg	Standard Deviation 3.297
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 4PM	7.95 mmHg	Standard Deviation 3.045
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 10AM	27.48 mmHg	Standard Deviation 3.45
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 10AM	27.41 mmHg	Standard Deviation 3.423
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 1: 8AM	29.19 mmHg	Standard Deviation 2.962
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 8AM	10.20 mmHg	Standard Deviation 3.958
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 4PM	26.12 mmHg	Standard Deviation 3.154
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 1: 8AM	9.49 mmHg	Standard Deviation 4.242
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 10AM	10.14 mmHg	Standard Deviation 2.935
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 1PM	26.27 mmHg	Standard Deviation 3.335
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 8AM	10.91 mmHg	Standard Deviation 3.623
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 4PM	7.64 mmHg	Standard Deviation 3.762
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7,14,28: 8AM	29.19 mmHg	Standard Deviation 2.962
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 10AM	26.70 mmHg	Standard Deviation 3.25
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7,14,28: 8AM	28.60 mmHg	Standard Deviation 2.656
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 1PM	6.66 mmHg	Standard Deviation 2.804
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 4PM	6.14 mmHg	Standard Deviation 3.011
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 8AM	7.91 mmHg	Standard Deviation 2.802
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 1PM	25.99 mmHg	Standard Deviation 2.863
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 1: 8AM	28.55 mmHg	Standard Deviation 2.728
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 1PM	6.69 mmHg	Standard Deviation 2.996
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 4PM	25.84 mmHg	Standard Deviation 3.243
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 10AM	7.60 mmHg	Standard Deviation 3.031
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 4PM	25.84 mmHg	Standard Deviation 3.243
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 7: 8AM	8.50 mmHg	Standard Deviation 3.343
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 1PM	7.16 mmHg	Standard Deviation 3.229
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 10AM	7.30 mmHg	Standard Deviation 2.397
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 1PM	25.99 mmHg	Standard Deviation 2.863
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 1: 8AM	8.16 mmHg	Standard Deviation 4.031
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 1PM	25.99 mmHg	Standard Deviation 2.863
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 4PM	5.79 mmHg	Standard Deviation 3.219
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 28: 10AM	7.06 mmHg	Standard Deviation 3.311
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 4PM	6.30 mmHg	Standard Deviation 3.746
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 28: 4PM	25.84 mmHg	Standard Deviation 3.243
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Change at Day 14: 8AM	8.94 mmHg	Standard Deviation 3.462
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 14: 10AM	26.70 mmHg	Standard Deviation 3.25
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II	Day 0: Baseline for Day 7: 10AM	26.70 mmHg	Standard Deviation 3.25

Comparison: Change at Day 1 8 AM: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.37790% CI: [-0.63, 2.08]ANCOVA

Comparison: Change at Day 1 8 AM: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.12190% CI: [-0.07, 2.59]ANCOVA

Comparison: Change at Day 7 8 AM: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.09890% CI: [0.01, 2.59]ANCOVA

Comparison: Change at Day 7 8 AM: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.05990% CI: [0.19, 2.74]ANCOVA

Comparison: Change at Day 7 10 AM: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.06890% CI: [0.13, 2.51]ANCOVA

Comparison: Change at Day 7 10 AM: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.06390% CI: [0.16, 2.62]ANCOVA

Comparison: Change at Day 7 1 PM: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.03890% CI: [0.32, 2.77]ANCOVA

Comparison: Change at Day 7 1 PM : Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.51290% CI: [-0.72, 1.68]ANCOVA

Comparison: Change at Day 7 1 PM: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.08890% CI: [0.05, 2.56]ANCOVA

Comparison: Change at Day 7 4 PM: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.0190% CI: [0.69, 3.04]ANCOVA

Comparison: Change at Day 7 4 PM: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.00590% CI: [0.88, 3.31]ANCOVA

Comparison: Change at Day 14 8 AM: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.75790% CI: [-1.15, 1.69]ANCOVA

Comparison: Change at Day 14 8 AM: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.6790% CI: [-1.04, 1.77]ANCOVA

Comparison: Change at Day 14 10 AM: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.21590% CI: [-0.32, 2.26]ANCOVA

Comparison: Change at Day 14 10 AM: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.47890% CI: [-0.74, 1.87]ANCOVA

Comparison: Change at Day 14 1 PM: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.73690% CI: [-1.04, 1.57]ANCOVA

Comparison: Change at Day 14 1 PM: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.90890% CI: [-1.41, 1.22]ANCOVA

Comparison: Change at Day 14 4 PM: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.04290% CI: [0.31, 2.89]ANCOVA

Comparison: Change at Day 14 4 PM: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.22890% CI: [-0.35, 2.28]ANCOVA

Comparison: Change at Day 28 8 AM: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.56290% CI: [-0.92, 1.91]ANCOVA

Comparison: Change at Day 28 8 AM: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.03290% CI: [0.43, 3.23]ANCOVA

Comparison: Change at Day 28 10 AM: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.12490% CI: [-0.09, 2.6]ANCOVA

Comparison: Change at Day 28 10 AM: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.08390% CI: [0.08, 2.77]ANCOVA

Comparison: Change at Day 28 1 PM: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.53390% CI: [-0.8, 1.78]ANCOVA

Comparison: Change at Day 28 1 PM: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.27690% CI: [-0.44, 2.15]ANCOVA

Comparison: Change at Day 28 4 PM: Analysis was based on ANCOVA model for effect of taprenepag alone compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.03390% CI: [0.41, 3.14]ANCOVA

Comparison: Change at Day 28 4 PM: Analysis was based on ANCOVA model for effect of taprenepag in combination with latanoprost compared to latanoprost alone on IOP reduction from baseline with treatment and baseline IOP as covariates.p-value: 0.19890% CI: [-0.3, 2.46]ANCOVA

Secondary

Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I

Time frame: Stage I: 8 AM, 10 AM, 1 PM, 4 PM on Day 0 (Baseline), 8 AM on Day 1, 8 AM, 10 AM, 1 PM, 4 PM on Day 7, and 14

Arm	Measure	Group	Value (MEAN)	Dispersion
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 1 PM	25.83 mmHg	Standard Deviation 3.279
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 10 AM	24.75 mmHg	Standard Deviation 1.916
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 4 PM	25.50 mmHg	Standard Deviation 3.403
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 1 PM	4.56 mmHg	Standard Deviation 2.524
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 10 AM	3.86 mmHg	Standard Deviation 1.768
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 8 AM	3.44 mmHg	Standard Deviation 3.964
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 10 AM	24.75 mmHg	Standard Deviation 1.916
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day0: Baseline for Day 1, 7, 14 8 AM	27.78 mmHg	Standard Deviation 1.847
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 4 PM	4.33 mmHg	Standard Deviation 2.88
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 1 PM	4.67 mmHg	Standard Deviation 3.255
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 10 AM	3.58 mmHg	Standard Deviation 3.064
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 8 AM	4.56 mmHg	Standard Deviation 2.957
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 1 8 AM	4.89 mmHg	Standard Deviation 2.302
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 1 PM	25.83 mmHg	Standard Deviation 3.279
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 4 PM	2.72 mmHg	Standard Deviation 1.95
Taprenepag 0.0025% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 4 PM	25.50 mmHg	Standard Deviation 3.403
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 1 PM	6.22 mmHg	Standard Deviation 2.498
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 10 AM	26.11 mmHg	Standard Deviation 2.494
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 1 PM	26.06 mmHg	Standard Deviation 2.965
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 4 PM	25.11 mmHg	Standard Deviation 3.113
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 10 AM	26.11 mmHg	Standard Deviation 2.494
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 1 PM	26.06 mmHg	Standard Deviation 2.965
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 4 PM	25.11 mmHg	Standard Deviation 3.113
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 1 8 AM	5.44 mmHg	Standard Deviation 3.154
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 8 AM	6.67 mmHg	Standard Deviation 1.644
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 10 AM	7.00 mmHg	Standard Deviation 3.219
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day0: Baseline for Day 1, 7, 14 8 AM	27.72 mmHg	Standard Deviation 1.693
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 4 PM	5.06 mmHg	Standard Deviation 4.083
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 8 AM	6.11 mmHg	Standard Deviation 3.518
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 10 AM	6.33 mmHg	Standard Deviation 2.559
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 1 PM	5.22 mmHg	Standard Deviation 2.673
Taprenepag 0.005% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 4 PM	3.94 mmHg	Standard Deviation 2.88
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 10 AM	7.56 mmHg	Standard Deviation 3.041
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 10 AM	25.94 mmHg	Standard Deviation 2.872
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 10 AM	25.94 mmHg	Standard Deviation 2.872
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 4 PM	6.08 mmHg	Standard Deviation 3.573
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 1 PM	7.86 mmHg	Standard Deviation 2.908
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 1 PM	25.08 mmHg	Standard Deviation 2.208
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 4 PM	24.86 mmHg	Standard Deviation 2.405
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 4 PM	24.86 mmHg	Standard Deviation 2.405
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 1 PM	6.53 mmHg	Standard Deviation 2.746
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 10 AM	7.67 mmHg	Standard Deviation 3.245
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 1 8 AM	7.72 mmHg	Standard Deviation 2.697
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 1 PM	25.08 mmHg	Standard Deviation 2.208
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 8 AM	8.44 mmHg	Standard Deviation 2.267
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 8 AM	8.28 mmHg	Standard Deviation 4.186
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 4 PM	7.25 mmHg	Standard Deviation 2.929
Taprenepag 0.01% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day0: Baseline for Day 1, 7, 14 8 AM	27.72 mmHg	Standard Deviation 2.403
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 10 AM	6.40 mmHg	Standard Deviation 4.754
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 10 AM	7.15 mmHg	Standard Deviation 4.301
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 4 PM	6.30 mmHg	Standard Deviation 5.296
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 8 AM	8.20 mmHg	Standard Deviation 3.885
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 1 PM	7.55 mmHg	Standard Deviation 3.947
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 10 AM	26.30 mmHg	Standard Deviation 1.285
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 1 8 AM	6.75 mmHg	Standard Deviation 2.875
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 1 PM	25.10 mmHg	Standard Deviation 2.289
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 1 PM	5.50 mmHg	Standard Deviation 4.419
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 8 AM	7.70 mmHg	Standard Deviation 3.994
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 4 PM	25.90 mmHg	Standard Deviation 2.237
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 1 PM	25.10 mmHg	Standard Deviation 2.289
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 4 PM	25.90 mmHg	Standard Deviation 2.237
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 10 AM	26.30 mmHg	Standard Deviation 1.285
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 4 PM	8.95 mmHg	Standard Deviation 3.787
Taprenepag 0.015% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day0: Baseline for Day 1, 7, 14 8 AM	28.45 mmHg	Standard Deviation 1.471
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 10 AM	27.44 mmHg	Standard Deviation 3.269
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 1 PM	5.14 mmHg	Standard Deviation 3.664
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 1 PM	28.03 mmHg	Standard Deviation 3.906
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 4 PM	27.11 mmHg	Standard Deviation 3.564
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 1 8 AM	7.75 mmHg	Standard Deviation 3.276
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 8 AM	9.58 mmHg	Standard Deviation 3.356
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 10 AM	26.53 mmHg	Standard Deviation 1.906
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 10 AM	6.16 mmHg	Standard Deviation 2.891
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 1 PM	6.50 mmHg	Standard Deviation 4.652
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 4 PM	5.53 mmHg	Standard Deviation 4.519
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 4 PM	6.44 mmHg	Standard Deviation 3.015
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 8 AM	6.86 mmHg	Standard Deviation 2.622
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 10 AM	5.56 mmHg	Standard Deviation 3.273
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day0: Baseline for Day 1, 7, 14 8 AM	29.81 mmHg	Standard Deviation 2.769
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 4 PM	26.41 mmHg	Standard Deviation 3.068
Taprenepag 0.02% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 1 PM	27.13 mmHg	Standard Deviation 3.009
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 4 PM	25.28 mmHg	Standard Deviation 1.925
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 4 PM	6.66 mmHg	Standard Deviation 3.744
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 1 8 AM	7.22 mmHg	Standard Deviation 4.459
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 10 AM	26.16 mmHg	Standard Deviation 2.507
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 8 AM	8.28 mmHg	Standard Deviation 5.701
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day0: Baseline for Day 1, 7, 14 8 AM	28.44 mmHg	Standard Deviation 1.887
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 4 PM	6.22 mmHg	Standard Deviation 4.021
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 10 AM	8.09 mmHg	Standard Deviation 4.274
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 1 PM	25.69 mmHg	Standard Deviation 2.191
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 1 PM	25.69 mmHg	Standard Deviation 2.191
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 4 PM	25.28 mmHg	Standard Deviation 1.925
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 1 PM	7.19 mmHg	Standard Deviation 2.93
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 1 PM	7.44 mmHg	Standard Deviation 3.351
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 10 AM	8.72 mmHg	Standard Deviation 4.137
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 8 AM	7.67 mmHg	Standard Deviation 4.373
Taprenepag 0.03% (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 10 AM	26.16 mmHg	Standard Deviation 2.507
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 10 AM	0.67 mmHg	Standard Deviation 3.085
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 10 AM	-0.33 mmHg	Standard Deviation 3.099
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 4 PM	-0.23 mmHg	Standard Deviation 2.94
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day0: Baseline for Day 1, 7, 14 8 AM	28.15 mmHg	Standard Deviation 2.625
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 4 PM	25.35 mmHg	Standard Deviation 2.907
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 1 8 AM	1.35 mmHg	Standard Deviation 2.702
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 4 PM	0.27 mmHg	Standard Deviation 1.804
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 1 PM	25.52 mmHg	Standard Deviation 2.742
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 10 AM	25.13 mmHg	Standard Deviation 2.519
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 8 AM	1.56 mmHg	Standard Deviation 2.962
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 4 PM	25.35 mmHg	Standard Deviation 2.907
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 8 AM	2.15 mmHg	Standard Deviation 3.224
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 14 1 PM	0.06 mmHg	Standard Deviation 2.794
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0: Baseline for Day 7 10 AM	25.13 mmHg	Standard Deviation 2.519
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Day 0:Baseline for Day 14 1 PM	25.52 mmHg	Standard Deviation 2.742
Taprenepag Vehicle (Stage I)	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I	Change at Day 7 1 PM	1.90 mmHg	Standard Deviation 2.546

Comparison: Change at Day 1 8 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.01190% CI: [1.34, 5.9]ANCOVA

Comparison: Change at Day 1 8 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.00490% CI: [1.91, 6.47]ANCOVA

Comparison: Change at Day 1 8 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [4.19, 8.75]ANCOVA

Comparison: Change at Day 7 8 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.1290% CI: [-0.14, 5.02]ANCOVA

Comparison: Change at Day 7 8 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.00590% CI: [1.97, 7.14]ANCOVA

Comparison: Change at Day 7 8 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [3.58, 8.75]ANCOVA

Comparison: Change at Day 7 8 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its Vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [2.91, 8.08]ANCOVA

Comparison: Change at Day 7 10 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.00990% CI: [1.56, 6.53]ANCOVA

Comparison: Change at Day 7 10 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [4.49, 9.5]ANCOVA

Comparison: Change at Day 7 1 PM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.06690% CI: [0.29, 5.02]ANCOVA

Comparison: Change at Day 7 1 PM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.00690% CI: [1.76, 6.5]ANCOVA

Comparison: Change at Day 7 1 PM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [3.76, 8.49]ANCOVA

Comparison: Change at Day 7 1 PM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.0190% CI: [1.53, 6.5]ANCOVA

Comparison: Change at Day 7 4 PM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.00690% CI: [1.91, 7.19]ANCOVA

Comparison: Change at Day 7 4 PM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.00290% CI: [2.66, 7.94]ANCOVA

Comparison: Change at Day 7 4 PM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [4.87, 10.16]ANCOVA

Comparison: Change at Day 14 8 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.26990% CI: [-0.91, 4.58]ANCOVA

Comparison: Change at Day 14 8 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.00990% CI: [1.75, 7.24]ANCOVA

Comparison: Change at Day 14 8 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [4.08, 9.57]ANCOVA

Comparison: Change at Day 14 10 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.02490% CI: [0.95, 5.76]ANCOVA

Comparison: Change at Day 14 10 AM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [2.82, 7.66]ANCOVA

Comparison: Change at Day 14 1 PM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.00390% CI: [2.11, 6.72]ANCOVA

Comparison: Change at Day 14 1 PM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [2.72, 7.33]ANCOVA

Comparison: Change at Day 14 4 PM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.10390% CI: [-0.02, 4.84]ANCOVA

Comparison: Change at Day 14 4 PM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: 0.01390% CI: [1.32, 6.18]ANCOVA

Comparison: Change at Day 14 4 PM: Analysis was based on ANCOVA model for effect of taprenepag compared to its vehicle with treatment and baseline IOP as covariates.p-value: <0.00190% CI: [3.53, 8.39]ANCOVA

Secondary

Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I

IOP was measured using Goldmann applanation tonometer. IOP was measured in both the eyes, and the eye with higher IOP reading at the 2 eligibility visits was referred as 'study eye' for efficacy assessment. If both the measurements were equal, right eye was selected as the study eye. IOP was measured twice in the same eye, and if the difference between 2 measurements was less than or equal to 2 mmHg, the mean of the 2 readings was recorded as the IOP at that time point. If the difference between 2 readings was greater than 2 mmHg, a third consecutive reading was taken and the median IOP was recorded as the IOP at that time point. Mean IOP was reported as the average of individual participants' mean or median IOP values.

Time frame: Stage I: 8 ante meridiem (AM) on Day 1, 8 AM, 10 AM, 1 post meridiem (PM), 4 PM on Day 7, and 14

Arm	Measure	Group	Value (MEAN)	Dispersion
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 1 PM	21.17 mmHg	Standard Deviation 2.525
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 10 AM	20.89 mmHg	Standard Deviation 1.635
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 10 AM	21.17 mmHg	Standard Deviation 2.165
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 4 PM	21.17 mmHg	Standard Deviation 3.491
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 1 PM	21.28 mmHg	Standard Deviation 2.078
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 8 AM	24.33 mmHg	Standard Deviation 4.737
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 4 PM	22.78 mmHg	Standard Deviation 3.914
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 8 AM	23.22 mmHg	Standard Deviation 3.563
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 1: 8 AM	22.89 mmHg	Standard Deviation 3.14
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 8 AM	21.61 mmHg	Standard Deviation 3.927
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 4 PM	20.06 mmHg	Standard Deviation 5.282
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 4 PM	21.17 mmHg	Standard Deviation 3.841
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 8 AM	21.06 mmHg	Standard Deviation 2.888
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 1 PM	20.83 mmHg	Standard Deviation 2.839
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 10 AM	19.11 mmHg	Standard Deviation 3.943
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 1: 8 AM	22.28 mmHg	Standard Deviation 3.709
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 10 AM	19.78 mmHg	Standard Deviation 2.74
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 1 PM	19.83 mmHg	Standard Deviation 3.269
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 10 AM	18.28 mmHg	Standard Deviation 3.501
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 4 PM	17.61 mmHg	Standard Deviation 3.935
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 1: 8 AM	20.00 mmHg	Standard Deviation 1.677
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 8 AM	19.44 mmHg	Standard Deviation 4.081
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 8 AM	19.28 mmHg	Standard Deviation 2.438
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 1 PM	18.56 mmHg	Standard Deviation 3.754
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 1 PM	17.22 mmHg	Standard Deviation 4.063
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 10 AM	18.39 mmHg	Standard Deviation 3.11
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 4 PM	18.78 mmHg	Standard Deviation 3.97
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 8 AM	20.75 mmHg	Standard Deviation 4.906
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 1: 8 AM	21.70 mmHg	Standard Deviation 3.425
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 8 AM	20.25 mmHg	Standard Deviation 4.584
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 10 AM	19.15 mmHg	Standard Deviation 4.429
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 1 PM	17.55 mmHg	Standard Deviation 3.905
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 4 PM	16.95 mmHg	Standard Deviation 3.954
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 10 AM	19.90 mmHg	Standard Deviation 4.858
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 1 PM	19.60 mmHg	Standard Deviation 5.254
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 4 PM	19.60 mmHg	Standard Deviation 5.004
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 10 AM	20.38 mmHg	Standard Deviation 2.888
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 1: 8 AM	22.06 mmHg	Standard Deviation 2.732
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 10 AM	21.89 mmHg	Standard Deviation 3.798
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 1 PM	22.89 mmHg	Standard Deviation 4.029
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 1 PM	20.63 mmHg	Standard Deviation 4.224
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 8 AM	22.94 mmHg	Standard Deviation 3.787
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 8 AM	20.22 mmHg	Standard Deviation 3.866
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 4 PM	20.67 mmHg	Standard Deviation 2.704
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 4 PM	20.88 mmHg	Standard Deviation 4.604
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 4 PM	19.06 mmHg	Standard Deviation 3.886
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 1 PM	18.50 mmHg	Standard Deviation 3.703
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 1: 8 AM	21.22 mmHg	Standard Deviation 4.214
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 4 PM	18.63 mmHg	Standard Deviation 3.926
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 10 AM	17.44 mmHg	Standard Deviation 3.803
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 10 AM	18.06 mmHg	Standard Deviation 4.724
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 1 PM	18.25 mmHg	Standard Deviation 4.359
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 8 AM	20.78 mmHg	Standard Deviation 3.42
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 8 AM	20.17 mmHg	Standard Deviation 5.75
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 8 AM	26.00 mmHg	Standard Deviation 4.843
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 10 AM	24.46 mmHg	Standard Deviation 2.463
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 8 AM	26.58 mmHg	Standard Deviation 4.592
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 10 AM	25.46 mmHg	Standard Deviation 4.293
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 1 PM	23.63 mmHg	Standard Deviation 2.909
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 4 PM	25.08 mmHg	Standard Deviation 3.154
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 14: 1 PM	25.46 mmHg	Standard Deviation 3.665
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 1: 8 AM	26.79 mmHg	Standard Deviation 4.335
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I	Day 7: 4 PM	25.58 mmHg	Standard Deviation 5.044

Secondary

Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II

Time frame: Stage II: 8 AM on Day 1; 8 AM, 10 AM, 1 PM, 4 PM on Days 7, 14, and 28

Arm	Measure	Group	Value (MEAN)	Dispersion
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 8 AM	18.34 mmHg	Standard Deviation 3.115
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 10 AM	17.26 mmHg	Standard Deviation 2.456
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 4 PM	17.79 mmHg	Standard Deviation 3.673
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 1: 8 AM	19.12 mmHg	Standard Deviation 3.514
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 8 AM	19.60 mmHg	Standard Deviation 3.794
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 8 AM	18.85 mmHg	Standard Deviation 3.439
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 4 PM	17.41 mmHg	Standard Deviation 3.452
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 1 PM	18.30 mmHg	Standard Deviation 3.787
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 1 PM	17.25 mmHg	Standard Deviation 3.184
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 4 PM	17.26 mmHg	Standard Deviation 2.962
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 10 AM	17.93 mmHg	Standard Deviation 3.341
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 1 PM	17.94 mmHg	Standard Deviation 3.912
Taprenepag 0.0025% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 10 AM	17.81 mmHg	Standard Deviation 3.848
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 10 AM	19.61 mmHg	Standard Deviation 4.209
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 8 AM	19.56 mmHg	Standard Deviation 3.288
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 4 PM	18.67 mmHg	Standard Deviation 3.69
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 1 PM	19.19 mmHg	Standard Deviation 3.092
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 8 AM	19.40 mmHg	Standard Deviation 3.308
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 1: 8 AM	21.91 mmHg	Standard Deviation 3.177
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 10 AM	19.44 mmHg	Standard Deviation 3.335
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 8 AM	19.76 mmHg	Standard Deviation 3.188
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 10 AM	18.96 mmHg	Standard Deviation 3.938
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 4 PM	19.35 mmHg	Standard Deviation 4.035
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 1 PM	19.33 mmHg	Standard Deviation 3.619
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 1 PM	18.68 mmHg	Standard Deviation 3.122
Taprenepag 0.005% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 4 PM	19.08 mmHg	Standard Deviation 3.394
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 4 PM	19.13 mmHg	Standard Deviation 4.396
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 1: 8 AM	20.61 mmHg	Standard Deviation 2.859
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 8 AM	19.68 mmHg	Standard Deviation 3.14
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 10 AM	18.61 mmHg	Standard Deviation 2.814
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 1 PM	18.73 mmHg	Standard Deviation 3.518
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 4 PM	18.27 mmHg	Standard Deviation 3.047
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 8 AM	19.72 mmHg	Standard Deviation 3.644
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 10 AM	19.44 mmHg	Standard Deviation 3.318
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 1 PM	18.96 mmHg	Standard Deviation 3.776
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 4 PM	18.31 mmHg	Standard Deviation 3.37
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 8 AM	20.28 mmHg	Standard Deviation 4.294
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 10 AM	19.74 mmHg	Standard Deviation 3.764
Taprenepag 0.01% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 1 PM	19.06 mmHg	Standard Deviation 3.399
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 1 PM	18.89 mmHg	Standard Deviation 3.219
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 8 AM	19.53 mmHg	Standard Deviation 3.572
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 8 AM	19.11 mmHg	Standard Deviation 3.28
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 10 AM	17.94 mmHg	Standard Deviation 2.551
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 4 PM	18.66 mmHg	Standard Deviation 3.117
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 4 PM	17.65 mmHg	Standard Deviation 2.998
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 10 AM	18.98 mmHg	Standard Deviation 3.318
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 1 PM	18.47 mmHg	Standard Deviation 2.396
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 1: 8 AM	19.39 mmHg	Standard Deviation 3.229
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 8 AM	18.83 mmHg	Standard Deviation 2.908
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 1 PM	18.02 mmHg	Standard Deviation 2.872
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 10 AM	18.38 mmHg	Standard Deviation 3.038
Taprenepag 0.015% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 4 PM	19.06 mmHg	Standard Deviation 2.772
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 4 PM	16.91 mmHg	Standard Deviation 4.32
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 1 PM	16.80 mmHg	Standard Deviation 4.219
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 1: 8 AM	18.76 mmHg	Standard Deviation 4.058
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 10 AM	16.66 mmHg	Standard Deviation 4.743
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 1 PM	16.52 mmHg	Standard Deviation 4.622
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 10 AM	16.80 mmHg	Standard Deviation 4.67
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 4 PM	17.12 mmHg	Standard Deviation 4.823
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 4 PM	16.98 mmHg	Standard Deviation 5.077
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 8 AM	17.97 mmHg	Standard Deviation 4.876
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 8 AM	17.41 mmHg	Standard Deviation 4.035
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 10 AM	16.86 mmHg	Standard Deviation 4.827
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 1 PM	16.68 mmHg	Standard Deviation 5.331
Taprenepag 0.02% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 8 AM	17.69 mmHg	Standard Deviation 4.58
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 8 AM	18.99 mmHg	Standard Deviation 3.644
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 10 AM	17.85 mmHg	Standard Deviation 3.282
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 1 PM	17.09 mmHg	Standard Deviation 3.057
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 1: 8 AM	19.69 mmHg	Standard Deviation 3.945
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 1 PM	17.39 mmHg	Standard Deviation 2.68
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 10 AM	17.67 mmHg	Standard Deviation 3.196
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 8 AM	18.67 mmHg	Standard Deviation 4.127
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 10 AM	17.34 mmHg	Standard Deviation 3.028
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 4 PM	17.56 mmHg	Standard Deviation 2.989
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 4 PM	18.26 mmHg	Standard Deviation 2.736
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 1 PM	17.35 mmHg	Standard Deviation 2.612
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 8 AM	18.28 mmHg	Standard Deviation 3.718
Taprenepag 0.03% (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 4 PM	18.56 mmHg	Standard Deviation 3.323
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 8 AM	20.10 mmHg	Standard Deviation 3.698
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 4 PM	19.70 mmHg	Standard Deviation 3.642
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 8 AM	20.69 mmHg	Standard Deviation 3.577
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 8 AM	19.66 mmHg	Standard Deviation 3.908
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 4 PM	20.06 mmHg	Standard Deviation 3.668
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 10 AM	19.10 mmHg	Standard Deviation 3.727
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 7: 1 PM	19.30 mmHg	Standard Deviation 3.032
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 10 AM	19.64 mmHg	Standard Deviation 3.966
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 10 AM	19.40 mmHg	Standard Deviation 3.485
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 1: 8 AM	20.39 mmHg	Standard Deviation 3.548
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 28: 1 PM	19.33 mmHg	Standard Deviation 3.204
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 4 PM	19.54 mmHg	Standard Deviation 3.361
Taprenepag Vehicle (Stage I)	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II	Day 14: 1 PM	18.83 mmHg	Standard Deviation 3.231

Secondary

Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage I

Percentage of participants who reached an IOP of less than or equal to (\<=) 18 mmHg by post-eligibility visit (Day 1) and maintained an IOP \<= 18 mm Hg across all post-eligibility visits in Stage I were reported. IOP was measured using Goldmann applanation tonometer.

Time frame: Stage I: Day 1 up to Day 14

Population: ITT population included all randomized participants who received at least 1 dose of study medication. LOCF method was used to impute missing values.

Arm	Measure	Value (NUMBER)
Taprenepag 0.0025% (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage I	0.0 percentage of participants
Taprenepag 0.005% (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage I	11.1 percentage of participants
Taprenepag 0.01% (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage I	11.1 percentage of participants
Taprenepag 0.015% (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage I	0.0 percentage of participants
Taprenepag 0.02% (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage I	11.1 percentage of participants
Taprenepag 0.03% (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage I	22.2 percentage of participants
Taprenepag Vehicle (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage I	0.0 percentage of participants

Secondary

Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage II

Percentage of participants who reached an IOP \<= 18 mmHg by post-eligibility visit (Day 1) and maintained an IOP \<= 18 mm Hg across all post-eligibility visits in Stage II were reported. IOP was measured using Goldmann applanation tonometer.

Time frame: Stage II: Day 1 up to Day 28

Population: ITT population included all randomized participants who received at least 1 dose of study medication. LOCF method was used to impute missing values.

Arm	Measure	Value (NUMBER)
Taprenepag 0.0025% (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage II	22.9 percentage of participants
Taprenepag 0.005% (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage II	2.8 percentage of participants
Taprenepag 0.01% (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage II	13.9 percentage of participants
Taprenepag 0.015% (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage II	8.3 percentage of participants
Taprenepag 0.02% (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage II	38.9 percentage of participants
Taprenepag 0.03% (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage II	16.7 percentage of participants
Taprenepag Vehicle (Stage I)	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage II	5.7 percentage of participants

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I

Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II

Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage I

Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage II

Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II

Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I

Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I

Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II

Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage I

Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage II